Last reviewed · How we verify
DAPTACEL®: DTaP
DAPTACEL is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins.
DAPTACEL is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins. Used for Active immunization against diphtheria, tetanus, and pertussis in infants and children (2 months to 6 years of age).
At a glance
| Generic name | DAPTACEL®: DTaP |
|---|---|
| Also known as | DAPTACEL® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
DAPTACEL contains inactivated diphtheria and tetanus toxoids along with acellular pertussis antigens. Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these three bacterial pathogens. This provides immunity against diphtheria, tetanus, and pertussis (whooping cough).
Approved indications
- Active immunization against diphtheria, tetanus, and pertussis in infants and children (2 months to 6 years of age)
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Fever
- Fussiness/irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents (PHASE3)
- Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
- Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age (NA)
- Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety (PHASE2)
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |